Truist Financial Corp Trims Stake in Novo Nordisk A/S $NVO

Key Points

• Truist Financial trimmed its stake in Novo Nordisk by 11.0% in Q4, selling 85,582 shares and now holds 695,164 shares valued at about $35.37 million.
• Novo Nordisk beat Q1 estimates with $1.01 EPS (vs. $0.90) and $12.43 billion revenue, while analysts show a consensus "Hold" rating and an average target price of $65.56.
• Near‑term positives include a new share repurchase programme and strong demand for the Wegovy pill, but risks—especially a potential price war with Eli Lilly and ongoing pricing pressure—could compress margins.

Truist Financial Corp trimmed its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 11.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 695,164 shares of the company's stock after selling 85,582 shares during the quarter. Truist Financial Corp's holdings in Novo Nordisk A/S were worth $35,370,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Guerra Advisors Inc bought a new stake in Novo Nordisk A/S during the third quarter worth about $25,000. WealthCollab LLC lifted its stake in Novo Nordisk A/S by 93.5% during the fourth quarter. WealthCollab LLC now owns 538 shares of the company's stock worth $27,000 after purchasing an additional 260 shares during the last quarter. American National Bank & Trust bought a new stake in Novo Nordisk A/S during the fourth quarter worth about $28,000. Maseco LLP bought a new stake in Novo Nordisk A/S during the fourth quarter worth about $29,000. Finally, Jackson Grant Investment Advisers Inc. bought a new stake in Novo Nordisk A/S during the fourth quarter worth about $29,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Trading Up 1.1%

NYSE NVO opened at $44.87 on Wednesday. Novo Nordisk A/S has a 1-year low of $35.12 and a 1-year high of $81.44. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61. The stock has a 50-day moving average of $38.45 and a 200-day moving average of $47.11. The firm has a market cap of $200.34 billion, a PE ratio of 12.93, a price-to-earnings-growth ratio of 10.54 and a beta of 0.77.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, beating analysts' consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The company had revenue of $12.43 billion during the quarter, compared to analyst estimates of $11.97 billion. As a group, sell-side analysts forecast that Novo Nordisk A/S will post 3.34 EPS for the current year.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Company announces a new share repurchase programme as part of an existing DKK 15 billion plan, supporting buybacks and shareholder returns. Novo Nordisk A/S - share repurchase programme
• Positive Sentiment: Coverage highlights Wegovy’s early pill rollout and strong demand, reinforcing Novo Nordisk’s leadership in GLP‑1 weight-loss treatments and suggesting continued revenue momentum. Novo Nordisk's Wegovy pill head start forces investors to rethink Eli Lilly's GLP-1 dominance
• Positive Sentiment: Safety signals tied to Eli Lilly’s Foundayo (FDA reports of serious liver events) may indirectly benefit Novo Nordisk by slowing competitor adoption and keeping market share growth for Wegovy and related products more favorable. FDA Reports Liver Failure in Patient Taking Eli Lilly’s Foundayo
• Positive Sentiment: Bullish investor pieces argue Q1 could mark an inflection (top- and bottom-line beats expected), and some investors are “doubling down” based on the growth runway for GLP‑1s and strategic pricing to expand market share. Novo Nordisk: My Q1 Preview And Why I'm Doubling Down
• Neutral Sentiment: Sector analysis notes GLP‑1s have reshaped pharma R&D value and improved returns, which supports longer‑term demand for Novo Nordisk products but also attracts competition and regulatory scrutiny. 'Bubble effect': Weight loss drug fueled growth is putting the pharma sector at risk, report finds
• Negative Sentiment: Reuters and other coverage warn a price war with Eli Lilly could compress margins — investors want evidence that rising prescriptions and volumes will offset lower prices. Novo Nordisk's weight-loss pill boom faces price war test
• Negative Sentiment: Pre‑earnings previews flag ongoing pricing pressure, potential weak guidance and tough competition from Eli Lilly as risks that could weigh on near‑term earnings and margins. Novo Nordisk Before Q1 Earnings: How Should Investors Play the Stock?

Analysts Set New Price Targets

Several brokerages have issued reports on NVO. Citigroup began coverage on Novo Nordisk A/S in a research note on Tuesday, January 27th. They set a "neutral" rating for the company. Jefferies Financial Group raised Novo Nordisk A/S from an "underperform" rating to a "hold" rating in a research note on Thursday, February 12th. TD Cowen lowered Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $42.00 price target for the company. in a research note on Tuesday, March 10th. Morgan Stanley raised Novo Nordisk A/S from an "underweight" rating to an "equal weight" rating and set a $40.00 price target for the company in a research note on Tuesday, March 3rd. Finally, Sanford C. Bernstein began coverage on Novo Nordisk A/S in a research note on Wednesday, March 18th. They set an "outperform" rating and a $175.00 price target for the company. Four analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Novo Nordisk A/S has a consensus rating of "Hold" and an average target price of $65.56.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.